Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1

Sponsor Class

INDUSTRY 44OTHER 42NETWORK 11NIH 4OTHER_GOV 2UNKNOWN 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colonic Neoplasms 1

Interventions

Paclitaxel 6Radiotherapy 3Epirubicin 3Radiotherapy, Intensity-Modulated 2Radiation Dose Hypofractionation 2Radiation 2Docetaxel 2Cyclophosphamide 2Cisplatin 2Carboplatin 2Capecitabine 2pegylated granulocyte colony-stimulating factor 1nabiximols 1aumolertinib 1Zoledronic Acid 1Vinorelbine 1Temozolomide 1TP protocol 1Standard of Care 1S 1 (combination) 1Platinum 1Pemetrexed 1Neoadjuvant Therapy 1Irinotecan 1Granulocyte Colony-Stimulating Factor 1Drug Therapy 1Decitabine 1Chemotherapy, Adjuvant 1Cetuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × UNKNOWN × Cetuximab × Clear all
NCT05074966 2021-10-12

The Efficacy and Safety of Modified XELOX(mXELOX) Plus Cetuximab vs FOLFOX Plus Cetuximab in RAS and BRAF WT mCRC Pts

ChineseAMS

Phase 3 Unknown
314 enrolled
Gastrointestinal

Colonic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡